

July 4, 2019  
Eisai Co., Ltd.

**EISAI SELECTED FIRST IN BIOTECHNOLOGY & PHARMACEUTICALS SECTOR  
AMONG MOST HONORED COMPANIES BY INSTITUTIONAL INVESTOR MAGAZINE**

Eisai Co., Ltd. (Eisai) announced today that it has been selected as first in Biotechnology & Pharmaceuticals sector in the All-Japan Executive Team released by Institutional Investor, a prominent U.S. financial magazine.

This survey ranks and honors the outstanding IR activities of Japanese companies based on the votes of institutional investors and analysts around the world, and 886 investors and analysts from 349 institutions participated in this survey in 2019. Eisai was placed first as the most honored company in the Biotechnology & Pharmaceuticals sector due to achievement in top-three appearances in the rankings of Best CEO, Best CFO, Best IR Professionals, and Best IR Programs.

Please go to the “Institutional Investor” magazine website for ranking details.

<https://www.institutionalinvestor.com/research/9302/The-All-Japan-Executive-Team>

Eisai’s corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. In order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.

End of documents